Drug Development

With a new CEO famed for a $2.4B exit and a reverse merger in play, Mentari Therapeutics isn't just developing drugs; it's building a powerhouse.

Lundbeck completes enrollment for a pivotal trial testing a novel drug for severe childhood epilepsies. But what are the real stakes for patients and investors?

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

Arch Biopartners is fast-tracking a novel therapy for diabetic kidney disease, targeting IL-32 to address a massive unmet medical need for millions globally.

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

Neurizon Therapeutics completes enrollment for its NUZ-001 ALS trial at record speed, accelerating the timeline for potential new treatment data to 2027.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

New biotech Rinascera launches with a veteran team and a clinical-stage pipeline. Is its disciplined, asset-acquisition strategy the future for rare diseases?

As OmniAb preps its Q2 results, the real story isn't just the numbers. It's the 'Biological Intelligence' platform reshaping drug discovery from the ground up.

With its MASH drug Rezdiffra a certified blockbuster, Madrigal's upcoming Q2 report will reveal if its meteoric rise can be sustained against new rivals.

With its lead gene therapy nearing pivotal data, enGene installs a new chairman with a track record of commercial success, signaling a critical shift from R&D to market readiness.

Curative Biotechnology secures a key U.S. patent for a metformin eye-drop, a novel approach that could transform treatment for macular degeneration.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

Beyond GLP-1, Boehringer Ingelheim’s new drug targets the brain's hunger signals, a calculated move in the high-stakes race for obesity treatment.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.

As Celldex nears pivotal data for its lead drug, the planned retirement of its long-serving CFO marks a strategic pivot toward becoming a commercial powerhouse.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

With a strategic investment from Persephoni, SelSym Biotech is advancing SymClot, a synthetic blood-clotting agent that could redefine emergency medicine.

As Corrixr's novel CRISPR therapy nears human trials, the appointment of Seagen veteran Nancy Whiting signals a strategic shift from lab to market.